N.Z. Biotech Uses New Law To Recover From Financial Problems
This article was originally published in PharmAsia News
Executive SummaryNew Zealand biotech ICP Biotechnology says it has taken advantage of new law to recover from financial problems. ICP Bio relies heavily on its new-proteins business, but sales were slowed by what the firm considers difficult market conditions. The "voluntary administration" law allows the firm to find a new investor that would allow ICP Bio to recaptalize, according to its chairman, Roger Gower. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.